Te
Tesaro (GSK)
Waltham MAFounded 2010500 employees
Private CapbiotechAcquiredOncology
Platform: Zejula PARP
Market Cap
N/A
All Drugs
2
Clinical Trials
3
Failed / Terminated
1
FDA Approved
0
Drug Pipeline (2 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| TES-8356 | TES-8356 | NDA/BLA | 2 | MET | Ewing Sarcoma | ||
| Tezetapinarof | TES-6339 | Phase 1 | 1 | JAK1 | T2DNASH |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (3)